31. März 2025 – Walder Wyss advised 65 Equity Partners in the acquisition of approximately 40% of the shares in HAS Healthcare Advanced Synthesis SA. At the same time, HAS Healthcare Advances Synthesis SA is acquiring Cerbios-Pharma SA to create a leading international group in the CDMO sector.

This major acquisition in Ticino, Switzerland will allow the two companies to combine their production capacities, chemical and biological expertise, know-how and technological capabilities. The move creates new opportunities for growth and drives business development to establish itself as a leading international quality provider in the CDMO (Contract Development and Manufacturing Organization) industry. 65 Equity Partners focuses on partnering with family-owned and entrepreneur-led businesses to drive long-term growth and innovation through similar M&A processes.

Walder Wyss advised 65 Equity Partners as Swiss legal advisor on the transaction. The team was led by Davide Jermini (Partner, Corporate/M&A) and Martina Madonna-Quadri (Senior Associate, Corporate/M&A). It included Andreas Wildi (Partner, Healthcare and Life Sciences), Stefano Codoni (Partner, Intellectual Property), Fabienne Limacher (Partner, Tax), Marco Galli (Counsel, Corporate/M&A), Alex Domeniconi (Managing Associate, Employment) and Celine Weber (Managing Associate, Healthcare & Life Sciences).